Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:57:29.127Z.
Consensus retrieved: 2026-10-06T13:22:07.794Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:57:29.127Z.
Quote observation: 2026-10-06T19:53:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 668cd0a27a378b9e576851b626ee3d167f0214c2770a49d8858259c0142eb795
Forward PE Ratio (N/A) = Dated Quote Price ($2.50) / Consensus Forward EPS ($-1.67)
FORWARD PE RATIO
N/A
Kiora Pharmaceuticals, Inc.
Market Cap
$11.08M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kiora Pharmaceuticals, Inc. (KPRX) | $11.08M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.13M | N/A |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.17M | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.19M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.25M | N/A |
| Pluri Inc. (PLUR)vs › | $11.33M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.38M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.74M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.67 | $-1.67 – $-1.67 | 1 | n/m |
| 2027-12-31 | $-0.85 | $-0.85 – $-0.85 | 1 | n/m |
| 2028-12-31 | $-0.96 | $-0.96 – $-0.96 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
